OraSure Technologies, Inc. (NASDAQ:OSUR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

New Director Appointment

On June21, 2017, Mara G. Aspinall was appointed as a new member
of the Board of Directors (the Board) of OraSure Technologies,
Inc. (the Company). Ms.Aspinall will serve as a Class II Director
with an initial term expiring at the Companys 2020 Annual Meeting
of Stockholders. Ms.Aspinall has also been appointed to serve on
the Boards Audit and Compensation Committees.

to the Companys Non-Employee Director Compensation Policy (the
Policy) and Stock Award Plan, Ms.Aspinall was granted an option
to purchase 40,000 shares of the Companys common stock with an
exercise price equal to the mean between the high and low sales
prices of the Companys common stock on the date of her
appointment. The foregoing option will vest on a monthly basis
over the 24-month period following the grant date. Vesting will
be accelerated in the event of a change in control involving the
Company. Ms.Aspinall will also receive fees and additional equity
compensation to the Policy.

A press release announcing Ms.Aspinalls appointment to the Board
is attached as Exhibit 99.1 to this Report and is incorporated by
reference herein.

Item9.01 financial Statements and Exhibits.

2

ORASURE TECHNOLOGIES INC Exhibit
EX-99.1 2 d405424dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Company contact:   Ronald H. Spair    Shauna White Chief Financial Officer    Corporate Marketing Manager 610-882-1820    484-353-1575 [email protected]    [email protected] www.orasure.com    www.orasure.com OraSure Technologies Appoints Mara G. Aspinall to Board of Directors BETHLEHEM,…
To view the full exhibit click here
About OraSure Technologies, Inc. (NASDAQ:OSUR)

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Its diagnostic products include tests, such as OraQuick Rapid HIV Test, OraQuick In-Home HIV Test, OraQuick HIV Self-Test, OraQuick HCV Rapid Antibody Test, OraQuick Ebola Rapid Antigen Test, OraSure QuickFlu Rapid Flu A&B Test, OraSure Collection Device, Molecular Collection Systems, Cryosurgical Systems (Skin Lesion Removal Products), Immunoassay Tests and Reagents, Western blot HIV-1 Confirmatory Test and Q.E.D. Saliva Alcohol Test. Its products are sold in the United States and internationally to clinical laboratories and hospitals.